Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
alpha-MSH versus placebo during oral glucose tolerance testing in adults with type 1 diabetes
ACTRN12622000832774Phase 2Completed
- Sponsor
- Monash University
- Start
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of alpha-melanocyte stimulating hormone in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Monash University. Primary endpoint: Two-hour area under the curve blood plasma glucose concentration. Started Sep 2022; status: completed.
02
Drugs
alpha-melanocyte stimulating hormone
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ACTRN12622000832774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000832774.